Epsikapron is a pharmaceutical drug used to treat bleeding disorders such as hemophilia. The spelling of the word follows the conventions of scientific nomenclature, with the prefix "epsi-" likely derived from the Greek "epsi", meaning "upon". "Kapron" refers to the chemical compound tranexamic acid, which is the active ingredient in Epsikapron. The correct IPA transcription would be /ɛpsiˈkæprɒn/, with emphasis on the second syllable. The spelling remains consistent across languages, reinforcing its scientific validity.